Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Monoclonal antibodies taken for multiple sclerosis (MS) while breastfeeding appears not to affect a child’s development during the first 3 years of life, according to results from a preliminary study.
Monoclonal antibodies taken for multiple sclerosis (MS) while breastfeeding appears not to affect a child’s development during the first 3 years of life, according to results from a preliminary study.
The US FDA has declined to approve glatiramer acetate depot 40mg (GA Depot 40), a long-acting investigational formulation of glatiramer acetate for the treatment of relapse-remitting multiple sclerosis (RRMS).
The US FDA has declined to approve glatiramer acetate depot 40mg (GA Depot 40), a long-acting investigational formulation of glatiramer acetate for the treatment of relapse-remitting multiple sclerosis (RRMS).
Emotional burden and pain severity were greater in patients with multiple sclerosis (MS) who had central neuropathic pain than those who had musculoskeletal pain.
Emotional burden and pain severity were greater in patients with multiple sclerosis (MS) who had central neuropathic pain than those who had musculoskeletal pain.
Sleep quality was associated with improved fatigue, depression, and quality of life (QOL) in patients with pediatric onset multiple sclerosis (POMS), according to findings from a cross-sectional study.
Sleep quality was associated with improved fatigue, depression, and quality of life (QOL) in patients with pediatric onset multiple sclerosis (POMS), according to findings from a cross-sectional study.
More than half of patients with relapsing-remitting multiple sclerosis (MS) who underwent autologous hematopoietic stem cell transplantation (aHSCT) experienced improved disability.
More than half of patients with relapsing-remitting multiple sclerosis (MS) who underwent autologous hematopoietic stem cell transplantation (aHSCT) experienced improved disability.
Before the onset of multiple sclerosis (MS), patients are nearly twice as likely to experience psychiatric comorbidity, according to a study published in Neurology.
Before the onset of multiple sclerosis (MS), patients are nearly twice as likely to experience psychiatric comorbidity, according to a study published in Neurology.
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
The US Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn), the first biosimilar of Tysabri (natalizumab) injection, for the treatment of adults with relapsing forms of multiple sclerosis (MS).
The US Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn), the first biosimilar of Tysabri (natalizumab) injection, for the treatment of adults with relapsing forms of multiple sclerosis (MS).
For individuals with radiologically isolated syndrome (RIS), early intervention with teriflunomide may prevent the time to development of multiple sclerosis (MS) by as much as 63%.
For individuals with radiologically isolated syndrome (RIS), early intervention with teriflunomide may prevent the time to development of multiple sclerosis (MS) by as much as 63%.
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click